journal
https://read.qxmd.com/read/38632314/kras-g12-mutations-as-adverse-prognostic-factors-in-kmt2a-rearranged-acute-myeloid-leukemia
#1
JOURNAL ARTICLE
Shinju Iyoda, Kenichi Yoshida, Kota Shoji, Nana Ito, Miu Tanaka, Yasuhito Nannya, Genki Yamato, Shinichi Tsujimoto, Norio Shiba, Yasuhide Hayashi, Yusuke Shiozawa, Yuichi Shiraishi, Kenichi Chiba, Ai Okada, Hiroko Tanaka, Satoru Miyano, Yuhki Koga, Hiroaki Goto, Hiroshi Moritake, Kiminori Terui, Etsuro Ito, Nobutaka Kiyokawa, Daisuke Tomizawa, Takashi Taga, Akio Tawa, Junko Takita, Momoko Nishikori, Souichi Adachi, Seishi Ogawa, Hidemasa Matsuo
No abstract text is available yet for this article.
April 18, 2024: Leukemia
https://read.qxmd.com/read/38632316/mutations-in-the-splicing-factor-sf3b1-are-linked-to-frequent-emergence-of-hla-dr-low-neg-monocytes-in-lower-risk-myelodysplastic-neoplasms
#2
JOURNAL ARTICLE
Susann Winter, Marie Schneider, Uta Oelschlaegel, Giulia Maggioni, Elena Riva, Marco Gabriele Raddi, Sara Bencini, Benedetta Peruzzi, Desmond Choy, Rita Antunes Dos Reis, Esther Güse, Christopher Lischer, Julio Vera, Jessica A Timms, Nicolas Sompairac, Katja Sockel, Antonella Poloni, Antje Tunger, Matteo Giovanni Della Porta, Valeria Santini, Marc Schmitz, Uwe Platzbecker, Shahram Kordasti
No abstract text is available yet for this article.
April 17, 2024: Leukemia
https://read.qxmd.com/read/38632315/prophylactic-donor-derived-cd19-car-t-cell-infusion-for-preventing-relapse-in-high-risk-b-all-after-allogeneic-hematopoietic-stem-cell-transplantation
#3
JOURNAL ARTICLE
Wenyi Lu, Hairong Lyu, Xia Xiao, Xue Bai, Meng Zhang, Jiaxi Wang, Yedi Pu, Juanxia Meng, Xiaomei Zhang, Haibo Zhu, Ting Yuan, Bing Wang, Xin Jin, Xinping Cao, Zhao Wang, Tianle Xie, Haotian Meng, Alexey V Stepanov, Alexander G Gabibov, Yuxin An, Rui Sun, Yu Zhang, Mikhail A Maschan, Zunmin Zhu, Hongkai Zhang, Mingfeng Zhao
No abstract text is available yet for this article.
April 17, 2024: Leukemia
https://read.qxmd.com/read/38627586/autophagy-degrades-immunogenic-endogenous-retroelements-induced-by-5-azacytidine-in-acute-myeloid-leukemia
#4
JOURNAL ARTICLE
Nandita Noronha, Chantal Durette, Maxime Cahuzac, Bianca E Silva, Justine Courtois, Juliette Humeau, Allan Sauvat, Marie-Pierre Hardy, Krystel Vincent, Jean-Philippe Laverdure, Joël Lanoix, Frédéric Baron, Pierre Thibault, Claude Perreault, Gregory Ehx
The hypomethylating agent 5-azacytidine (AZA) is the first-line treatment for AML patients unfit for intensive chemotherapy. The effect of AZA results in part from T-cell cytotoxic responses against MHC-I-associated peptides (MAPs) deriving from hypermethylated genomic regions such as cancer-testis antigens (CTAs), or endogenous retroelements (EREs). However, evidence supporting higher ERE MAPs presentation after AZA treatment is lacking. Therefore, using proteogenomics, we examined the impact of AZA on the repertoire of MAPs and their source transcripts...
April 16, 2024: Leukemia
https://read.qxmd.com/read/38622290/correction-to-histone-deacetylase-hdac-inhibitor-acy241-enhances-anti-tumor-activities-of-antigen-specific-central-memory-cytotoxic-t-lymphocytes-against-multiple-myeloma-and-solid-tumors
#5
Jooeun Bae, Teru Hideshima, Yu-Tzu Tai, Yan Song, Paul Richardson, Noopur Raje, Nikhil C Munshi, Kenneth C Anderson
No abstract text is available yet for this article.
April 15, 2024: Leukemia
https://read.qxmd.com/read/38615117/combination-therapies-with-ponatinib-and-asciminib-in-a-preclinical-model-of-chronic-myeloid-leukemia-blast-crisis-with-compound-mutations
#6
JOURNAL ARTICLE
Nikola Curik, Adam Laznicka, Vaclava Polivkova, Jitka Krizkova, Eva Pokorna, Pavel Semerak, Pavla Suchankova, Pavel Burda, Andreas Hochhaus, Katerina Machova Polakova
No abstract text is available yet for this article.
April 13, 2024: Leukemia
https://read.qxmd.com/read/38609496/fluorescence-in-situ-hybridization-reveals-the-evolutionary-biology-of-minor-clone-of-gain-amp-1q-in-multiple-myeloma
#7
JOURNAL ARTICLE
Jian Cui, Yuntong Liu, Rui Lv, Wenqiang Yan, Jingyu Xu, Lingna Li, Chenxing Du, Tengteng Yu, Shuaishuai Zhang, Shuhui Deng, Weiwei Sui, Mu Hao, Shuhua Yi, Dehui Zou, Lugui Qiu, Yan Xu, Gang An
Growing evidence suggests that gain or amplification [gain/amp(1q)] accumulates during disease progression of multiple myeloma (MM). Previous investigations have indicated that small gain/amp(1q) subclones present at the time of diagnosis may evolve into dominant clones upon MM relapse. However, the influence of a minor clone of gain/amp(1q) on MM survival, as well as the correlation between different clonal sizes of gain/amp(1q) and the chromosomal instability (CIN) of MM, remains poorly understood. In this study, we analyzed fluorescence in situ hybridization (FISH) results of 998 newly diagnosed MM (NDMM) patients...
April 12, 2024: Leukemia
https://read.qxmd.com/read/38609495/metabolic-reprogramming-regulated-by-traf6-contributes-to-the-leukemia-progression
#8
JOURNAL ARTICLE
Shinichiro Matsui, Chihiro Ri, Lyndsey C Bolanos, Kwangmin Choi, Asuka Shibamiya, Arata Ishii, Koji Takaishi, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yusuke Takeda, Naoya Mimura, Akihide Yoshimi, Koutaro Yokote, Daniel T Starczynowski, Emiko Sakaida, Tomoya Muto
TNF receptor associated factor 6 (TRAF6) is an E3 ubiquitin ligase that has been implicated in myeloid malignancies. Although altered TRAF6 expression is observed in human acute myeloid leukemia (AML), its role in the AML pathogenesis remains elusive. In this study, we showed that the loss of TRAF6 in AML cells significantly impairs leukemic function in vitro and in vivo, indicating its functional importance in AML subsets. Loss of TRAF6 induces metabolic alterations, such as changes in glycolysis, TCA cycle, and nucleic acid metabolism as well as impaired mitochondrial membrane potential and respiratory capacity...
April 12, 2024: Leukemia
https://read.qxmd.com/read/38600316/combination-p53-activation-and-bcl-x-l-bcl-2-inhibition-as-a-therapeutic-strategy-in-high-risk-and-relapsed-acute-lymphoblastic-leukemia
#9
JOURNAL ARTICLE
Hayden L Bell, Helen J Blair, Samantha J Jepson Gosling, Martin Galler, Daniel Astley, Anthony V Moorman, Olaf Heidenreich, Gareth J Veal, Frederik W van Delft, John Lunec, Julie A E Irving
Due to the rarity of TP53 mutations in acute lymphoblastic leukemia (ALL), p53 re-activation by antagonism of the p53-MDM2 interaction represents a potential therapeutic strategy for the majority of ALL. Here, we demonstrate the potent antileukemic activity of the MDM2 antagonist idasanutlin in high-risk and relapsed ex vivo coculture models of TP53 wildtype ALL (n = 40). Insufficient clinical responses to monotherapy MDM2 inhibitors in other cancers prompted us to explore optimal drugs for combination therapy...
April 10, 2024: Leukemia
https://read.qxmd.com/read/38600315/management-of-isocitrate-dehydrogenase-1-2-mutated-acute-myeloid-leukemia
#10
REVIEW
Harry Fruchtman, Zachary M Avigan, Julian A Waksal, Nicole Brennan, John O Mascarenhas
The emergence of next generation sequencing and widespread use of mutational profiling in acute myeloid leukemia (AML) has broadened our understanding of the heterogeneous molecular basis of the disease. Since genetic sequencing has become a standard practice, several driver mutations have been identified. Accordingly, novel targeted therapeutic agents have been developed and are now approved for the treatment of subsets of patients that carry mutations in FLT3, IDH1, and IDH2 [1, 2]. The emergence of these novel agents in AML offers patients a new modality of therapy, and shifts treatment paradigms toward individualized medicine...
April 10, 2024: Leukemia
https://read.qxmd.com/read/38600314/genome-wide-dna-methylation-analysis-of-blastic-plasmacytoid-dendritic-cell-neoplasm-identifies-distinct-molecular-features
#11
JOURNAL ARTICLE
Axel Künstner, Julian Schwarting, Hanno M Witte, Pengwei Xing, Veronica Bernard, Stephanie Stölting, Philipp Lohneis, Florian Janke, Maede Salehi, Xingqi Chen, Kathrin Kusch, Holger Sültmann, Emil Chteinberg, Anja Fischer, Reiner Siebert, Nikolas von Bubnoff, Hartmut Merz, Hauke Busch, Alfred C Feller, Niklas Gebauer
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) constitutes a rare and aggressive malignancy originating from plasmacytoid dendritic cells (pDCs) with a primarily cutaneous tropism followed by dissemination to the bone marrow and other organs. We conducted a genome-wide analysis of the tumor methylome in an extended cohort of 45 BPDCN patients supplemented by WES and RNA-seq as well as ATAC-seq on selected cases. We determined the BPDCN DNA methylation profile and observed a dramatic loss of DNA methylation during malignant transformation from early and mature DCs towards BPDCN...
April 10, 2024: Leukemia
https://read.qxmd.com/read/38594348/treatment-patterns-for-al-amyloidosis-after-frontline-daratumumab-bortezomib-cyclophosphamide-and-dexamethasone-treatment-failures
#12
JOURNAL ARTICLE
Saurabh Zanwar, Morie A Gertz, Eli Muchtar, Francis K Buadi, Taxiarchis Kourelis, Wilson Gonsalves, Ronald S Go, Suzanne Hayman, Prashant Kapoor, Moritz Binder, Joselle Cook, David Dingli, Nelson Leung, Yi Lin, Rahma Warsame, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Robert A Kyle, S Vincent Rajkumar, Shaji Kumar, Angela Dispenzieri
No abstract text is available yet for this article.
April 9, 2024: Leukemia
https://read.qxmd.com/read/38580835/pre-frailty-after-blood-or-marrow-transplantation-and-the-risk-of-subsequent-mortality
#13
JOURNAL ARTICLE
Nora Balas, Joshua S Richman, Wendy Landier, Sadeep Shrestha, Katia J Bruxvoort, Lindsey Hageman, Qingrui Meng, Elizabeth Ross, Alysia Bosworth, F Lennie Wong, Ravi Bhatia, Stephen J Forman, Saro H Armenian, Daniel J Weisdorf, Smita Bhatia
We examined the prevalence, risk factors, and association between pre-frailty and subsequent mortality after blood or marrow transplantation (BMT). Study participants were drawn from the BMT Survivor Study (BMTSS) and included 3346 individuals who underwent BMT between 1974 and 2014 at one of three transplant centers and survived ≥2 years post-BMT. Participants completed the BMTSS survey at a median of 9 years from BMT and were followed for subsequent mortality for a median of 5 years after survey completion...
April 5, 2024: Leukemia
https://read.qxmd.com/read/38575672/loss-of-hematopoietic-progenitors-heterogeneity-is-an-adverse-prognostic-factor-in-lower-risk-myelodysplastic-neoplasms
#14
JOURNAL ARTICLE
Charles Dussiau, Thibault Comont, Camille Knosp, Inès Vergnolle, Clotilde Bravetti, Alban Canali, Amandine Houvert, Laetitia Largeaud, Christian Daveaux, Laila Zaroili, Chloé Friedrich, Ismaël Boussaid, Loria Zalmai, Carole Almire, Odile Rauzy, Lise Willems, Rudy Birsen, Didier Bouscary, Michaela Fontenay, Olivier Kosmider, Nicolas Chapuis, François Vergez
Myelodysplastic neoplasms (MDS) are characterized by clonal evolution starting from the compartment of hematopoietic stem and progenitors cells (HSPCs), leading in some cases to leukemic transformation. We hypothesized that deciphering the diversity of the HSPCs compartment may allow for the early detection of an emergent sub-clone that drives disease progression. Deep analysis of HSPCs repartition by multiparametric flow cytometry revealed a strong disorder of the hematopoietic branching system in most patients at diagnosis with different phenotypic signatures closely related to specific MDS features...
April 4, 2024: Leukemia
https://read.qxmd.com/read/38575671/i%C3%AE%C2%BAb%C3%AE%C2%B5-deficiency-accelerates-disease-development-in-chronic-lymphocytic-leukemia
#15
JOURNAL ARTICLE
Jessica Bordini, Chiara Lenzi, Michela Frenquelli, Alessia Morabito, Athanasios Pseftogas, Daniela Belloni, Larry Mansouri, George Tsiolas, Eleonora Perotta, Pamela Ranghetti, Francesca Gandini, Francesca Genova, Daniel Hägerstrand, Georgios Gavriilidis, Sofoklis Keisaris, Nikolaos Pechlivanis, Frederic Davi, Neil E Kay, Anton W Langerak, Sarka Pospisilova, Lydia Scarfò, Antonios Makris, Fotis E Psomopoulos, Kostas Stamatopoulos, Richard Rosenquist, Alessandro Campanella, Paolo Ghia
The NFKBIE gene, which encodes the NF-κB inhibitor IκBε, is mutated in 3-7% of patients with chronic lymphocytic leukemia (CLL). The most recurrent alteration is a 4-bp frameshift deletion associated with NF-κB activation in leukemic B cells and poor clinical outcome. To study the functional consequences of NFKBIE gene inactivation, both in vitro and in vivo, we engineered CLL B cells and CLL-prone mice to stably down-regulate NFKBIE expression and investigated its role in controlling NF-κB activity and disease expansion...
April 4, 2024: Leukemia
https://read.qxmd.com/read/38575670/high-plex-imaging-and-cellular-neighborhood-spatial-analysis-reveals-multiple-immune-escape-and-suppression-patterns-in-diffuse-large-b-cell-lymphoma
#16
JOURNAL ARTICLE
David J Reiss, Yumi Nakayama, Andrew P Weng, Matthew E Stokes, Laurie Sehn, Christian Steidl, David W Scott, C Chris Huang, Anita K Gandhi
No abstract text is available yet for this article.
April 4, 2024: Leukemia
https://read.qxmd.com/read/38555405/a-complex-interplay-of-intra-and-extracellular-factors-regulates-the-outcome-of-fetal-and-adult-derived-mll-rearranged-leukemia
#17
JOURNAL ARTICLE
Maria Jassinskaja, Sudip Ghosh, Joanna Watral, Mina Davoudi, Melina Claesson Stern, Ugarit Daher, Mohamed Eldeeb, Qinyu Zhang, David Bryder, Jenny Hansson
Infant and adult MLL1/KMT2A-rearranged (MLLr) leukemia represents a disease with a dismal prognosis. Here, we present a functional and proteomic characterization of in utero-initiated and adult-onset MLLr leukemia. We reveal that fetal MLL::ENL-expressing lymphomyeloid multipotent progenitors (LMPPs) are intrinsically programmed towards a lymphoid fate but give rise to myeloid leukemia in vivo, highlighting a complex interplay of intra- and extracellular factors in determining disease subtype. We characterize early proteomic events of MLL::ENL-mediated transformation in fetal and adult blood progenitors and reveal that whereas adult pre-leukemic cells are mainly characterized by retained myeloid features and downregulation of ribosomal and metabolic proteins, expression of MLL::ENL in fetal LMPPs leads to enrichment of translation-associated and histone deacetylases signaling proteins, and decreased expression of inflammation and myeloid differentiation proteins...
March 30, 2024: Leukemia
https://read.qxmd.com/read/38553571/the-role-of-quiescent-thymic-progenitors-in-tal-lmo2-induced-t-all-chemotolerance
#18
JOURNAL ARTICLE
Kevin W O'Connor, Kensei Kishimoto, Irena O Kuzma, Kelsey P Wagner, Jonathan S Selway, Justine E Roderick, Keshab K Karna, Kayleigh M Gallagher, Kai Hu, Haibo Liu, Rui Li, Michael A Brehm, Lihua Julie Zhu, David J Curtis, Cedric S Tremblay, Michelle A Kelliher
Relapse in T-cell acute lymphoblastic leukemia (T-ALL) may signify the persistence of leukemia-initiating cells (L-ICs). Ectopic TAL1/LMO expression defines the largest subset of T-ALL, but its role in leukemic transformation and its impact on relapse-driving L-ICs remain poorly understood. In TAL1/LMO mouse models, double negative-3 (DN3; CD4- CD8- CD25+ CD44- ) thymic progenitors harbored L-ICs. However, only a subset of DN3 leukemic cells exhibited L-IC activity, and studies linking L-ICs and chemotolerance are needed...
March 29, 2024: Leukemia
https://read.qxmd.com/read/38548962/management-and-outcome-of-patients-with-chronic-myeloid-leukemia-in-blast-phase-in-the-tyrosine-kinase-inhibitor-era-analysis-of-the-european-leukemianet-blast-phase-registry
#19
JOURNAL ARTICLE
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Elena Morozova, Aleksandra Golos, Philipp Ernst, Ulla Olsson-Stromberg, Daniela Zackova, Franck E Nicolini, Han Bao, Fausto Castagnetti, Elzbieta Patkowska, Jiri Mayer, Klaus Hirschbühl, Helena Podgornik, Edyta Paczkowska, Anne Parry, Thomas Ernst, Astghik Voskanyan, Elzbieta Szczepanek, Susanne Saussele, Georg-Nikolaus Franke, Alexander Kiani, Edgar Faber, Stefan Krause, Luis Felipe Casado, Krzysztof Lewandowski, Matthias Eder, Peter Anhut, Justyna Gil, Thomas Südhoff, Holger Hebart, Sonja Heibl, Markus Pfirrmann, Andreas Hochhaus, Michael Lauseker
Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015...
March 28, 2024: Leukemia
https://read.qxmd.com/read/38548961/mitigating-immortal-time-bias-exploring-osteonecrosis-and-survival-in-pediatric-all-aall0232-trial-insights
#20
JOURNAL ARTICLE
Shyam Srinivasan, Swaminathan Keerthivasagam
No abstract text is available yet for this article.
March 28, 2024: Leukemia
journal
journal
20191
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.